Drug Profile
Research programme: anti-Hsp90 antibodies - Biotecnol/Pharmis
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Biotecnol SA; Pharmis Biofarmaceutica
- Class Antibodies
- Mechanism of Action HSP90 heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Portugal (Parenteral)
- 14 Jun 2012 Preclinical development is ongoing Portugal
- 30 May 2007 Preclinical trials in Cancer in Portugal (Parenteral)